Keyphrases
Type 2 Diabetes Mellitus (T2DM)
90%
Interleukin-6
85%
Randomized Clinical Trial
83%
Randomized Controlled Trial
63%
Exercise-induced
45%
Exercise Effect
42%
Tocilizumab
39%
Gastric Emptying
36%
Interleukin-6 Receptor (IL-6R)
36%
Exercise Training
35%
Glycemic Control
35%
Dietary Weight Loss
33%
Epicardial Adipose Tissue
33%
Receptor Blockade
33%
Diabetes Secondary
33%
Gastric Emptying Rate
33%
Multi-arm
33%
Exercise-induced Changes
33%
Visceral Adipose Tissue
33%
Glucagon-like
26%
Physical Activity
26%
Adipose Tissue Mass
26%
New-onset Type 2 Diabetes
23%
Type 2 Diabetic Patients
23%
During Exercise
22%
Abdominal Obesity
20%
Delayed Gastric Emptying
20%
Exercise Adaptation
20%
Obese Men
20%
Resistance Exercise
20%
Advanced Glycation End Products
20%
Lifestyle Intervention
20%
Aerobic Exercise
19%
Group Randomized
18%
Skeletal muscle
18%
Metformin Treatment
16%
IL-6 Inhibition
16%
Receptor for Advanced Glycation End Products
16%
Left Ventricular Strain
16%
SRAGE
16%
Double-blind Randomized Clinical Trial
16%
β-cell Function
16%
Metformin
16%
Skeletal muscle Adaptation
16%
Group-randomized Trial
16%
Exercise-based
16%
Pancreatic Cells
16%
Continuous Glucose Monitoring
16%
Glycemic Variability
16%
Human Immune Cells
16%
Medicine and Dentistry
Randomized Clinical Trial
100%
Maturity Onset Diabetes of the Young
88%
Stomach Emptying
50%
Interleukin 6
45%
Adipose Tissue
35%
Arm
33%
Cell Function
33%
Glycemic Control
33%
Randomized Controlled Trial
32%
Exercise
27%
Physical Activity
25%
Glucagon Like Peptide 1
23%
Resistance Training
23%
Tocilizumab
22%
Advanced Glycation End-Product
22%
Skeletal Muscle
21%
Beta Cell
21%
Oxidative Stress
20%
Aerobic Exercise
19%
Patient with Type 2 Diabetes
18%
Lifestyle Intervention
18%
Glycon
16%
Glycemic
16%
Systematic Review
16%
Secretion (Process)
16%
Standing
16%
Interleukin 6 Receptor
16%
Receptor Blocking
16%
Advanced Glycation End Product Receptor
16%
Endurance Training
14%
Diet Therapy
12%
Glucagon
11%
Receptor
11%
Body Mass Index
9%
Creatinine
7%
Adverse Event
6%
Placebo
6%
Abdominal Obesity
5%
Stomach Paresis
5%
